BC Innovations | May 30, 2019
Emerging Company Profile

Aro delivers bispecifics, siRNAs where others can’t

A year after its launch, Susan Dillon and Karyn O’Neil’s Aro has begun to reveal details about how the J&J spinout’s Centyrins could form small bispecifics and stable siRNA therapies to penetrate hard-to-reach cancers. Therapies...
Items per page:
1 - 1 of 1